CBTN Cell Lines High-Throughput Drug Screening Study (NCATS)

Email Principal Investigator


Asset 14.png

Mateusz Koptyra

Children’s Hospital of Philadelphia
Philadelphia, PA, USA

CBTN Specimen


CBTN Participants

CBTN Pre-clinical Models


Internal funding

National Institute of Health

About this


While the understanding of pediatric brain cancers has grown over time, there are still very limited options for targeted treatments. One reason for this is the inefficiency of current analysis methods and a lack of centralization of such data for rare pediatric brain tumors. Here, researchers propose a collaborative effort with the National Center For Advancing Translational Studies (NCATS). This work will utilize a high volume screening approach that will find novel drug possibilities by testing the CBTN tumor models. Through automated robotic screening, the technology interrogates the drug dose-response relationship with speed and accuracy. As the ultimate goal, this project will provide extensive drug response information from over 1,000 FDA approved drugs across multiple pediatric tumor diagnoses, guiding clinical decision making. The generated data will create a baseline to explore new tumor specific biomarkers/signaling pathways as drug targets. The data generated will utilize rare cell lines provided by the Children’s Brain Tumor Network (CBTN), and all data will be returned to CBTN and available for researchers without restrictions.

Ask The


Ask the scientists

What are the goals of this project?

Researchers will build a resource that provides insight into the drug response of various pediatric tumor types for therapeutic development and use.

What is the impact of this project?

A guiding resource of this kind will be accessible to cancer researchers around the world, broadening the therapeutic impact of this project.

Why is the CBTN request important to this project?

The Children’s Brain Tumor Network will provide rare specimens that will make this work possible.

Specimen Data

The Children's Brain Tumor Network is contributing to this project by providing cell lines.